Browse more cannabis research, findings, methods, and limitations.
Cannabis extracts from four different plant varieties all inhibited liver enzymes that metabolize warfarin and other blood thinners — with interaction strength varying by chemotype.
A 12-week group therapy program combining CBT and motivational enhancement reduced cannabis use, cravings, withdrawal, depression, and anxiety in treatment-seeking patients.
National survey found most cannabis use happens at home with few household rules restricting it, creating potential secondhand exposure for non-users.
EU-GEI study of 2,112 people found cannabis use partially mediates the relationship between childhood adversity and first-episode psychosis.
Study of 323 cannabis use disorder patients found most had pre-existing adverse childhood experiences, social-emotional impairments, or neurodevelopmental conditions.
Lab study found THC at physiological concentrations impaired sperm capacitation and altered gene expression in a bull sperm model.
Population study of 34,309 West Virginia births found cannabis common in prenatal substance use, both alone and combined with opioids and stimulants.
Rat study reveals a novel FABP5-CB2 cannabinoid receptor pathway in the prefrontal cortex that regulates anxiety behavior.
Proof-of-concept RCT compared cannabis alone, oxycodone alone, and cannabis+oxycodone for fibromyalgia pain to test opioid-sparing potential.
Michigan study found nausea and vomiting of pregnancy associated with prenatal cannabis use amid rising potency and decreasing risk perception.
NHANES analysis of 18,000+ adults found cannabis use associated with lower odds of some GI illnesses, contrasting with hyperemesis reports in heavy users.
Systematic review finds marijuana smoking linked to airway inflammation, chronic bronchitis, and possible associations with pneumonia and emphysema.
Rome police seizures show hashish THC nearly doubled from 13.7% to 27.1% in seven years, with some samples exceeding 40% — and young males are the primary users.
Real-world study found prescribed CBD reduced seizures in a substantial proportion of epilepsy patients over 12 months with mostly mild side effects.
Cross-sectional study of 153 substance-dependent patients in North India found ADHD prevalent across substance types including cannabis dependence.
Cross-sectional study finds cannabis use linked to adverse psychosocial functioning among North American college students, extending adolescent findings to ages 18-22.
Novel cannabis chemovar index classified products by cannabinoid-terpene profiles and found different combinations associated with distinct patient outcomes in 204 users.
One in four positive workplace drug tests now contain delta-8 THC metabolites — 11% from delta-8 exclusively — creating new challenges for testing programs and employees alike.
Interrupted time series analysis found Washington State traffic crashes increased after marijuana legalization and especially after retail store openings.
ABCD Study found limited concordance between teen self-reported substance use and hair toxicology, with hair testing detecting use teens denied.
ABCD Study of 5,580 youth found secondhand cannabis and tobacco smoke exposure associated with lower cognitive scores, even without direct use.
Survey of US cannabis flower purchases found prices and sources varied significantly across state legal frameworks in 2019-2020.
Study of 15,311 Canadian cannabis consumers found proximity to legal retail stores strongly predicted legal purchasing in the first 3 years of legalization.
Survey of 15,311 Canadian consumers found legal cannabis sourcing varied widely by product type, province, and use frequency from 2019-2021.
Survey of 39 states and DC found cannabis record expungement options widely available but varying dramatically in accessibility and scope.
Survey found almost no US film incentive programs restrict cannabis or tobacco depictions, despite evidence that media exposure influences youth substance initiation.
Five high-CBD cannabis extracts reduced gut cell inflammation through microRNA pathways, suppressing COX-2, IL-6, and IL-8 — but high doses also slowed cell growth.
UK Medical Cannabis Registry analysis found fibromyalgia patients improved on quality-of-life measures after at least one month of cannabis-based treatment.
Analysis of a CUD clinical trial found high-dose nabiximols did not cause clinically significant changes in biological markers including liver function.
Systematic review finds roadside cannabis screening devices detect THC presence but struggle to reliably indicate impairment, highlighting a key legalization challenge.
Review finds cannabis increases psychosis risk, worsens outcomes in vulnerable youth, and recommends integrated treatment approaches for co-occurring use and psychotic symptoms.
Prospective study found whole-blood cannabinoid profiles differed between symptomatic and asymptomatic periods in ED patients with suspected cannabinoid hyperemesis syndrome.
Analysis of CHS Reddit communities identified common triggers, home remedies, and patient experiences with cannabinoid hyperemesis syndrome.
Observational study found medical cannabis associated with changes in controlled substance prescriptions, including opioid-sparing effects and sedative hypnotic pattern changes.
Study found significant disagreements between web-based and government cannabis retailer data across US states, raising concerns for access research accuracy.
Population study of 150,634 California teens found e-cigarettes, cigarettes, and cannabis each independently associated with asthma, with additive combined effects.
Animal study found THC and CBD had distinct effects on BDNF and TrkB expression in the adolescent hippocampus, suggesting different impacts on brain development.
Scoping review finds growing cannabis use among older adults but limited evidence on age-specific safety, efficacy, and drug interaction concerns.
Case report of CHS presenting with ventricular bigeminy highlights potential cardiac complications of cannabinoid hyperemesis syndrome.
Review proposes neuropsychological testing to differentiate cannabis-induced psychosis from schizophrenia, conditions that often look identical clinically.
Survey of 344 Pennsylvania clinicians found most felt insufficiently trained and uncomfortable discussing medical cannabis with patients.
Longitudinal study found continued cannabis use predicted worse outcomes in first-episode psychosis, with early intervention services only partially offsetting the disadvantage.
Cannabinoids — especially CBD — show biological rationale for treating psoriasis through antioxidant and anti-inflammatory pathways, but clinical evidence in human patients remains minimal.
Scoping review of human lab cannabis self-administration studies identifies factors influencing consumption and highlights potential for testing CUD medications.
Mouse study found a hemoglobin-derived peptide promoted deep sleep through CB1 cannabinoid receptors, revealing new endocannabinoid sleep regulation pathways.
Survey reveals widespread public belief that marijuana effectively treats glaucoma, contrasting with ophthalmological consensus that it is impractical for this use.
Propensity-matched study found medical cannabis authorization associated with increased ED visits and hospitalization for depressive disorders.
Review finds growing interest in medical cannabis for hand surgery pain but limited specific evidence, with opioid-sparing potential as the main driver.
Analysis of 214,505 US adults found cannabis use rising from 2015-2019 across disabilities and health conditions, exceeding general population rates.
Study found tobacco dependence worsened cannabis withdrawal symptoms in both people with and without schizophrenia-spectrum disorders.